Research Paper Volume 12, Issue 21 pp 21706—21729

Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways

Figure 8. Puerarin inhibits ROS levels by upregulating HO-1 and downregulating TRAF6. (A) Representative western blot images show the HO-1 protein levels in the control and HO-1 knockdown RAW264.7 cells. (B) The histogram plots show the relative HO-1 levels in the control and HO-1 knockdown RAW264.7 cells. Note: n=3 per group; **P <0.01. (C) Representative western blots show the levels of C-fos, MMP9 and CTSK in the control and HO-1 knockdown RAW264.7 cells treated with RANKL or RANKL+puerarin. (DF) The histogram plots show the levels of C-fos, MMP9 and CTSK proteins in the control and HO-1 knockdown, RAW264.7 cells treated with RANKL or RANKL+puerarin. Note: n=3 per group, **P <0.01. (G) Western blot analysis shows the TRAF6 protein levels in the control and TRAF6 overexpressing RAW264.7 cells. (H) The histogram plots show the relative TRAF6 protein levels in the control and TRAF6 overexpressing RAW264.7 cells. Note: n=3 per group; **P <0.01. (I) Representative western blots show the levels of C-fos, MMP9 and CTSK in the control and TRAF6 overexpressing RAW264.7 cells treated with RANKL or RANKL+puerarin (JL) The histogram plots show the levels of C-fos, MMP9 and CTSK proteins in the control and TRAF6 overexpressing RAW264.7 cells treated with RANKL or RANKL+puerarin. Note: n=3 per group; *P <0.05, **P <0.01.